Sort
4,870 grants matching “glp 1”
Treatment of pulmonary fibrosis with inhibitors of integrin alphavbeta1.
$1,517,775Dean Sheppard · University Of California, San Francisco · UH3 · FY2018 · HL
Translational Gene Therapy for CNGB1 Retinitis Pigmentosa
$1,517,749Simon Petersen-Jones · Michigan State University · R24 · FY2022 · EY
Disease Modifying Analgesia with CA8 Gene Therapy
$1,516,241Roy Clifford Levitt · University Of Miami School Of Medicine · UG3 · FY2021 · NS
Inhaled IRK inhibitors as a novel therapeutic for IPF
$1,515,600David L Hava · Metera Pharmaceuticals, Inc. · R44 · FY2020 · HL
Small Molecule Inhibitors of Smallpox Virus Replication
$1,513,613Robert Jordan · Siga Technologies, Inc. · R44 · FY2006 · AI
Potentiating an Anthrax DNA Vaccine with Electroporation
$1,505,125Ichor Medical Systems, Inc. · R42 · FY2005 · AI
Influenza vaccination using a microneedle patch
$1,503,781Mark R Prausnitz · Georgia Institute Of Technology · U01 · FY2011 · EB
RBD recombinant protein-based SARS vaccine for biodefense
$1,501,840Peter J Hotez · Baylor College Of Medicine · R01 · FY2012 · AI
A Randomized Phase 2A Clinical Trial Pioneering the Utility of an eNAMPT-Reducing Therapy in ARDS/VILI: the PUERTA Trial
$1,500,000Joe G. N. Garcia · Aqualung Therapeutics Corp. · R44 · FY2023 · HL
Treatment of congenital heart disease associated pulmonary hypertension
$1,500,000Andrew L Salzman · Radikal Therapeutics, Inc. · R44 · FY2015 · HD
IND- and NDA-enabling toxicology studies for PTI-125, a novel small molecule for Alzheimer's disease
$1,500,000Lindsay H Burns · Cassava Sciences, Inc · R44 · FY2016 · AG
Clinical Phase I trials on an IND single molecule dual inhibitor of Cav3 channels and soluble epoxide hydrolase for treatment of neuropathic pain
$1,499,931Xinmin Simon Xie · Afasci, Inc. · R44 · FY2024 · NS
Clinical Phase I trials on an IND single molecule dual inhibitor of Cav3 channels and soluble epoxide hydrolase for treatment of neuropathic pain
$1,499,931Xinmin Simon Xie · Afasci, Inc. · R44 · FY2023 · NS
Development of modified human thioredoxin as an inhaled biologic therapeutic for cystic fibrosis
$1,499,635Peter B Heifetz · Orpro Therapeutics, Inc. · R44 · FY2018 · HL
Development of a novel lipase inhibitor for the treatment of acute pancreatitis
$1,498,822Gabi Hanna · Lamassu Pharma Inc. · R44 · FY2020 · DK
LcrV Plague Vaccine with Altered Immune Modulatory Properties
$1,498,357Olaf Schneewind · University Of Chicago · U01 · FY2007 · AI
Development of a TRAIL-based therapy for alcohol related chronic pancreatitis
$1,498,190Victor V Roschke · Theraly Fibrosis, Inc. · U44 · FY2020 · AA
GMP Production of a Tau Oligomer Inhibitor to Enable Clinical Development forADRD
$1,497,873James G. Moe · Oligomerix, Inc · R44 · FY2024 · AG
GMP Production of a Tau Oligomer Inhibitor to Enable Clinical Development forADRD
$1,496,276James G. Moe · Oligomerix, Inc · R44 · FY2023 · AG
DEVELOPMENT OF SAPONIN DMLT ADJUVANT (SDA)
$1,493,832Elizabeth Norton · Tulane University Of Louisiana · N01 · FY2025 · AI
Aging Well with HIV through Alcohol Research and Risk Reduction and Education (AWAR3E) Center
$1,493,442Amy Caroline Justice · Yale University · P60 · FY2025 · AA
Translational Gene Therapy for Rhodopsin Autosomal Dominant Retinitis Pigmentosa
$1,492,362William A. Beltran · University Of Pennsylvania · R24 · FY2012 · EY
IND-enabling studies on novel Cav3 T-channel modulators for treatment of neuropathic pain
$1,491,977Xinmin Simon Xie · Afasci, Inc. · R44 · FY2018 · NS
IND-enabling studies on novel Cav3 T-channel modulators for treatment of neuropathic pain
$1,491,584Xinmin Simon Xie · Afasci, Inc. · R44 · FY2020 · NS
Advancing a broad-spectrum anti-influenza A virus RNA packaging inhibitor to an IND
$1,489,636Jeffrey S Glenn · Stanford University · R01 · FY2018 · AI